Search PubMed⌕ Search

Biomedical subjects

H Ball

Publications and source records attributed to H Ball.

42 records · Page 3Linked to original sources
PubMed1988

Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.

Thirty-eight patients with advanced or recurrent carcinoma of the endometrium who had received no prior chemotherapy were placed on study by the Gynecologic Oncology Group. One was deemed histologically ineligible. Three patients had insufficient trials to evaluate response. Of the remaining 34 who received hexamethylmelamine 280 mg/m2 orally daily on Days 1 through 14 of each 4-week course, there were only three objective responses, two complete and one partial. Although toxicity was tolerable, hexamethylmelamine has minimal activity in advanced or recurrent endometrial carcinoma at the dose and schedule tested.

Adult↗
PubMed1986

2-Phenylindenes: development of a new mammary tumor inhibiting antiestrogen by combination of estrogenic side effect lowering structural elements.

A new antiestrogenic, mammary tumor inhibiting 2-phenylindene was developed by the use of structural elements that we have shown to decrease estrogenic side effects but to increase antiestrogenic activity and retain the antitumor effect of certain stilbenes. The new 2-phenylindenes were synthesized from their corresponding methoxy-substituted 3,4-diphenylhexane-3,4-diols by cyclization with acetyl chloride and acetic anhydride and subsequent ether cleavage and acetylation. In this series, the 2-phenylindene derivative (compound 13) with a 5,6,3',4'-tetraacetoxy and a 1-methyl-3-ethyl substitution had the highest affinity for the estrogen receptor, the strongest antiestrogenic effect, and the lowest estrogenic effect. This compound was superior to the 2-phenylindenes with 5,3'-diacetoxy substitution or 1,1-dimethyl and 3-isopropyl moieties, respectively. Compound 13 exhibited a strong, significant inhibiting effect on the growth of the hormone-dependent MXT mouse mammary tumor without estrogenic side effects.

Animals↗
PubMed1986

Catechol estrogens of the 1,1,2-triphenylbut-1-ene type: relationship between structure, estradiol receptor affinity, estrogenic and antiestrogenic properties, and mammary tumor inhibiting activities.

1,1,2-Triphenylbut-1-enes (26-35), which are substituted with one or two 3,4-diacetoxy groups or with one 3,4-diacetoxy and one 3- or 4-acetoxy group in two aromatic rings, were synthesized. The occurring E and Z isomers were isolated, and their identity was established by 1H NMR spectroscopy. A study on structure-activity relationship was carried out with regard to estradiol receptor affinity in vitro, estrogenic and antiestrogenic properties in the immature mouse, and inhibition of the hormone-dependent MXT mammary tumor of the mouse in vivo. Among the tested compounds, most of the 1,1-disubstituted 1,1,2-triphenylbut-1-enes (29, Z-30, Z,E-31) and (E)-1-(3-acetoxyphenyl)-1-phenyl-2-(3,4-diacetoxyphenyl)but- 1-ene (E-35) as well as its respective Z isomer (Z-35) exerted antiestrogenic properties. Compounds Z-30, Z,E-31, Z-35, and E-35 inhibited the growth of the hormone-dependent MXT tumor. The best antitumor effect without estrogenic side effects during therapy was shown by E-35.

Alkenes↗
PubMed1985

Acetoxy-substituted 1,1,2-triphenylbut-1-enes with antiestrogenic and mammary tumor inhibiting properties.

1,1,2-Triphenylbut-1-enes (E- and Z-10-12), which are substituted with one p- and one m-acetoxy group in two different aromatic rings, were synthesized. The E and Z isomers were isolated, and their identity was established by 1H NMR spectroscopy. A study of the structure-activity relationship was carried out with regard to estradiol receptor affinity in vitro, estrogenic and antiestrogenic properties (mouse), inhibition of the hormone-dependent human MCF7 breast cancer cell line in vitro, and the hormone-dependent MXT mammary tumor of the mouse in vivo. Among the tested compounds, (E)- and (Z)-1-(3-acetoxyphenyl)-1-(4-acetoxyphenyl)-2-phenylbut-1-enes+ ++ (E-10 and Z-10) and (Z)-1-(3-acetoxyphenyl)-1-phenyl-2-(4-acetoxyphenyl)-but-1-ene (Z-12) proved to be partial antiestrogens, which lead to an inhibition of the MCF7 cell line. They exert a growth-inhibiting activity on the hormone-dependent MXT mammary carcinoma of the mouse. In the case of E-10 and Z-10, this effect is only slightly weaker than that of 1,1-bis(4-acetoxyphenyl)-2-phenylbut-1-ene (13) and tamoxifen. Under the applied experimental conditions, there were no significant changes of uterine weight as an indicator of estrogenic side effects.

Alkenes↗
PubMedDate not supplied

Developing a quality management strategy.

A collaborative strategy between a college of nursing and a specialist nursing service was devised using outcomes driven by the ENB Higher Award. The successful implementation of this strategy has shown that the expectations of increased clinical-based innovation, resulting from this new approach to practitioner development, are achievable.

Humans↗